Wednesday, March 4, 2026 3/4/2026

Management and Data Coordination Unit for PCDC

Award Number: U24CA274496
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2027

Group Awards By:

View Award Description

Management and Data Coordination Unit for PCDC - PROJECT SUMMARY Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, partially owing to lack of effective biomarkers and/or screening strategies. The 5-year survival of patients with localized PDAC is 39% compared to 3% in patients diagnosed with metastatic disease, which indicates that detecting PDAC at early stage positively impacts survival. A centrally curated/managed multi-institution biospecimen resource containing prospectively collected, well-annotated biospecimens representing clinically relevant, diverse PDAC screening populations is desperately needed. The overall goal of the Pancreatic Cancer Detection Consortium (PCDC) Management and Data Coordinating Center (MDCU) is to facilitate the PCDC’s role in developing and utilizing high quality, well annotated samples for PDAC biomarker discovery, triage, pre-validation, and validation. The PCDC consortium is composed of multiple U01 Research Units (RU) and the MDCU, with NCI cooperation and central biospecimen storage at the NCI Frederick Central Repository. We will leverage our expertise and knowledge gained during the previous grant cycle to reinforce existing and new PCDC initiatives through expanded coordination, and strengthening the infrastructure to support management of the PCDC Reference Sets and Signature Protocols. Our Specific Aims are 1) To provide outstanding and timely administrative coordination and logistical support for the Pancreatic Cancer Detection Consortium. 2) To strategically plan, coordinate and implement the development of a well-annotated, uniformly collected and managed central PCDC biorepository and database. 3) To provide the highest quality biostatistical leadership of PCDC collaborative experimental design, study conduct, and analysis, and to provide biostatistical consultation to PCDC RUs. The strengths of the MDCU are the breadth and depth of knowledge and understanding of PDAC provided by MDCU personnel who will innovatively apply time tested infrastructure tools and strategies to consortium management, and our vast experience in enhancing the scientific needs of PCDC collaborative research. Our multidisciplinary team is committed to continue its leadership and contribution to the PCDC organization to advance the early detection of pancreatic cancer.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Detection and Diagnosis Research	000	4	12/18/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $659,850 )
2025	2025	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Detection and Diagnosis Research	001	4	8/20/2025	NON-COMPETING CONTINUATION	$429,319
2025	2025	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Detection and Diagnosis Research	002	4	9/23/2025	NON-COMPETING CONTINUATION	$230,531
2025	2024	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Detection and Diagnosis Research	000	3	4/24/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $659,850

Issue Date FY: 2024 ( Subtotal = $626,858 )
2024	2024	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Detection and Diagnosis Research	002	3	9/9/2024	NON-COMPETING CONTINUATION	$626,858
2024	2023	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Detection and Diagnosis Research	001	2	7/22/2024	NON-COMPETING CONTINUATION	$0
2024	2022	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Detection and Diagnosis Research	000	1	2/5/2024	NEW	$0
														Subtotal = $626,858

Issue Date FY: 2023 ( Subtotal = $646,653 )
2023	2023	MAYO CLINIC	200 1ST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Detection and Diagnosis Research	001	2	8/8/2023	NON-COMPETING CONTINUATION	$646,653
2023	2022	MAYO CLINIC	200 FIRST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Detection and Diagnosis Research	000	1	3/7/2023	NEW	$0
														Subtotal = $646,653

Issue Date FY: 2022 ( Subtotal = $659,848 )
2022	2022	MAYO CLINIC	200 FIRST ST SW	ROCHESTER	MN	55905	OLMSTED	USA	Cancer Detection and Diagnosis Research	000	1	8/29/2022	NEW	$659,848
														Subtotal = $659,848

Grand Total All Awards = $2,593,209

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Management and Data Coordination Unit for PCDC

Award Number: U24CA274496

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer